Zydus Cadila has received the tentative approval from the USFDA to market Apremilast Tablets (US RLD Otezla) 10 mg, 20 mg, and 30 mg. This medication is used to treat a certain type of arthritis (psoriatic arthritis) and a certain type of skin condition (moderate to severe
plaque psoriasis). It is also used to treat mouth sores in people who have Behcet's disease, a type of inflammatory disorder and helps to reduce the pain and improve the healing of these mouth sores. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
